Bullet-shaped suppository from white-yellow to yellow. Non-uniformity of coloring in the form of inclusions or marbling is allowed. On the longitudinal section there is a funnel-shaped depression. Suppository diameter no more.
The composition of the medicinal product
1 suppository Viferon 150000 ME contains the active substance: interferon alpha-2b human recombinant 150000 ME, excipients: ascorbic acid, sodium ascorbate, α-tocopheryl acetate, disodium edetate dihydrate, polysorbate-80, cocoa butter, confectionery fat or cocoa butter substitute before.
1 suppository Viferon 500000 ME contains the active substance: interferon alpha-2b human recombinant 500000 ME, excipients: ascorbic acid, sodium ascorbate, α-tocopheryl acetate, disodium edetate dihydrate, polysorbate-80, cocoa butter, confectionery fat or cocoa butter substitute before.
1 suppository Viferon 1000000 ME contains the active substance: interferon alpha-2b human recombinant 1000000 ME, excipients: ascorbic acid, sodium ascorbate, α-tocopheryl acetate, disodium edetate dihydrate, polysorbate-80, cocoa butter, confectionery fat or cocoa butter substitute before.
1 suppository Viferon 3000000 ME contains the active substance: interferon alpha-2b human recombinant 3000000 ME, excipients: ascorbic acid, sodium ascorbate, α-tocopheryl acetate, disodium edetate dihydrate, polysorbate-80, cocoa butter, confectionery fat or cocoa butter substitute before.
Pharmacotherapeutic group
Interferon alfa-2b.
ATC code: L03AB01
Pharmacodynamics
Interferon alfa-2b human recombinant, which is the active substance of the drug Viferon, rectal suppositories, has antiviral, immunomodulatory mediated antibacterial and antiproliferative properties. The antiviral effect of interferon alfa-2b is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by an increase in cell-mediated reactions. immune system. Interferon increases the cytotoxicity of T-lymphocytes, natural killers, phagocytic activity of macrophages, promotes the differentiation of T-helpers, protects T-cells from apoptosis. The immunomodulatory effect of interferon is also due to the influence on the production of a number of cytokines (interleukins, interferon gamma). All these effects of interferon may mediate its therapeutic activity.
Pharmacokinetics
Own studies of the pharmacokinetics of interferon alfa-2b as part of the drug Viferon, rectal suppositories have not been conducted, there are no data on systemic absorption. There are separate literature data describing the systemic absorption of interferon during rectal administration of suppositories containing interferon alfa-2b.
Indications for use
In the complex therapy of various infectious and inflammatory diseases in children, including newborns and premature infants: acute respiratory viral infections, including influenza, including those complicated by bacterial infection, pneumonia (bacterial, viral, chlamydial), meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis ); in complex therapy in adults, including pregnant women, with urogenital infection (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis), primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild and moderate course, including urogenital form; in the complex therapy of acute respiratory viral infections, including influenza, including those complicated by a bacterial infection in adults.
Method of application and dosage
The drug is used rectally. 1 suppository contains as active substance interferon alpha-2b human recombinant in the indicated dosages (150,000 ME, 500,000 ME, 1,000,000 ME, 3,000,000 ME).
In the complex therapy of various infectious and inflammatory diseases in newborns, including premature babies: newborns, including premature babies with a gestational age of more than 34 weeks, are prescribed Viferon 150,000 ME daily, 1 suppository 2 times a day after 12 hours. The course of treatment is 5 days.
Premature newborns with a gestational age of less than 34 weeks are prescribed VIFERON® 150,000 ME daily, 1 suppository 3 times a day after 8 hours. The course of treatment is 5 days.
The recommended number of courses for various infectious diseases inflammatory diseases in children, including newborns and premature babies: SARS, including influenza, including those complicated by a bacterial infection - 1-2 courses;
pneumonia (bacterial, viral, chlamydial) - 1-2 courses, sepsis - 2-3 courses,
meningitis - 1-2 courses, herpes infection - 2 courses, enterovirus infection - 1-2 courses, cytomegalovirus infection - 2-3 courses, mycoplasmosis, candidiasis, including visceral, - 2-3 courses. The break between courses is 5 days. According to clinical indications, therapy can be continued.
In complex therapy in adults, including pregnant women, with urogenital infection (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, human papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis), with primary or recurrent herpetic infection of the skin and mucous membranes ( localized form, mild and moderate course, including urogenital form).
Adults, with the above infections, except for herpetic infections, are prescribed Viferon 500,000 IU, 1 suppository 2 times a day after 12 hours. The course is 5-10 days. According to clinical indications, therapy can be continued with intervals between courses of 5 days.
In case of herpetic infection, Viferon 1,000,000 IU is prescribed, 1 suppository 2 times a day after 12 hours. The course of treatment is 10 days or more in case of recurrent infection. It is recommended to start treatment immediately when the first signs of skin and mucous membrane lesions (itching, burning, redness) appear. In the treatment of recurrent herpes, it is advisable to start treatment
in the prodromal period or at the very beginning of the manifestation of signs of relapse.
In pregnant women with urogenital infection, including herpes, in the second trimester of pregnancy (starting from week 14) - Viferon 500,000 ME 1 suppository every 12 hours (2 times a day) for 10 days, then 1 suppository every 12 hours ( 2 times a day) twice a week - 10 days. Then, after 4 weeks, prophylactic courses of the drug Viferon 150,000 ME are carried out, 1 suppository every 12 hours - for 5 days, the prophylactic course is repeated every 4 weeks. If necessary, it is possible to conduct a treatment course before childbirth.
In the complex therapy of acute respiratory viral infections, including influenza, including those complicated by a bacterial infection in adults
Apply Viferon 500000 ME 1 suppository 2 times a day every 12 hours daily. The course of treatment is 5-10 days.
Side effect
In rare cases, it is possible to develop allergic reactions(skin rash, itching). These phenomena are reversible and disappear 72 hours after discontinuation of the drug.
| NOSOLOGY | CHILDREN** | ADULTS |
|---|---|---|
| SARS and influenza | 5 days VIFERON up to 7 years 150,000ME over 7 years old 500,000ME 1 time at 12 noon |
5-10 days VIFERON 500,000ME |
| herpetic infection | 5 days VIFERON 150,000ME 1 time at 12 noon |
10 days VIFERON 1,000,000 ME Pregnant* ME 500,000 |
| urogenital infections, including papillomavirus infection |
5 days VIFERON 150,000ME 1 time at 12 noon |
5-10 days VIFERON 500,000ME Pregnant* ME 500,000 |
* From the 14th week of pregnancy.
** Premature newborns with a gestational age of less than 34 weeks are recommended to use the drug VIFERON 150,000 IU daily, 1 suppository 3 times a day after 8 hours.
FULL VERSION INSTRUCTIONS VIFERON SUPPLIES (SUPPOSITTORIES)
Instructions for use of the medicinal product for medical use VIFERON
Registration number: P N000017/01
Tradename drug: VIFERON
INN or grouping name: interferon alfa-2b
Dosage form: rectal suppositories
Compound
1 suppository VIFERON 150000 IU contains the active substance: interferon alpha-2b human recombinant 150000 IU, excipients: ascorbic acid 0.0054 g, sodium ascorbate 0.0108 g, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0.0001 g, polysorbate-80 0.0001 g, cocoa butter 0.1958 g, confectionery fat or cocoa butter substitute up to 1 g.
1 suppository VIFERON 500000 IU contains the active substance: interferon alpha-2b human recombinant 500000 IU, excipients: ascorbic acid 0.0081 g, sodium ascorbate 0.0162 g, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0.0001 g, polysorbate-80 0.0001 g, cocoa butter 0.1941 g, confectionery fat or cocoa butter substitute up to 1 g.
1 suppository VIFERON 1000000 IU contains the active substance: interferon alpha-2b human recombinant 1000000 IU, excipients: ascorbic acid 0.0081 g, sodium ascorbate 0.0162 g, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0 0001 g, polysorbate-80 0.0001 g, cocoa butter 0.1941 g, confectionery fat or cocoa butter substitute up to 1 g.
1 suppository VIFERON 3000000 IU contains the active substance: interferon alpha-2b human recombinant 3000000 IU, excipients: ascorbic acid 0.0081 g, sodium ascorbate 0.0162 g, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0 0001 g, polysorbate-80 0.0001 g, cocoa butter 0.1941 g, confectionery fat or cocoa butter substitute up to 1 g.
Description
Bullet-shaped suppository from white-yellow to yellow. Non-uniformity of coloring in the form of inclusions or marbling is allowed. On the longitudinal section there is a funnel-shaped depression. The diameter of the suppository is not more than 10 mm.
Pharmacotherapeutic group
Cytokine.
ATX code:
L03AB05.
pharmachologic effect
Interferon alpha-2b human recombinant has antiviral, immunomodulatory, antiproliferative properties, inhibits the replication of RNA and DNA-containing viruses. The immunomodulatory properties of interferon alpha-2b, such as increased phagocytic activity of macrophages, increased specific cytotoxicity of lymphocytes to target cells, determine its mediated antibacterial activity.
In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of interferon alpha-2b increases, its immunomodulatory effect is enhanced, which makes it possible to increase the efficiency of the body's own immune response to pathogenic microorganisms. When using the drug, the level of class A secretory immunoglobulins increases, the level of immunoglobulin E normalizes, and the functioning of the endogenous system of interferon alfa-2b is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and regenerating properties. It has been established that when using the drug VIFERON there are no side effects that occur during parenteral administration of interferon alfa-2b preparations, antibodies are not formed that neutralize the antiviral activity of interferon alfa-2b. The use of VIFERON as part of complex therapy makes it possible to reduce therapeutic doses of antibacterial and hormonal drugs, as well as to reduce the toxic effects of this therapy.
Cocoa butter contains phospholipids, which make it possible not to use synthetic toxic emulsifiers in production, and the presence of polyunsaturated fatty acids facilitates the administration and dissolution of the drug.
Indications for use
acute respiratory viral infections, including influenza, including those complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy;
infectious and inflammatory diseases of newborns, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy;
chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of severe activity, complicated by liver cirrhosis;
infectious and inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults as part of complex therapy;
primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild and moderate course, including the urogenital form in adults.
Contraindications
Hypersensitivity to any of the components of the drug.
Use during pregnancy and during breastfeeding
The drug is approved for use from the 14th week of pregnancy. Has no restrictions for use during breastfeeding.
Dosage and administration
The drug is used rectally. 1 suppository contains human recombinant interferon alfa-2b as an active substance in the indicated dosages (150,000 IU, 500,000 IU, 1,000,000 IU, 3,000,000 IU).
Acute respiratory viral infections, including influenza, including those complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy.
Read more…
The recommended dose for adults, including pregnant women and children over 7 years old, is VIFERON 500,000 IU, 1 suppository 2 times a day every 12 hours daily for 5 days. According to clinical indications, therapy can be continued.
Children under 7 years of age, including newborns and premature babies with a gestational age of more than 34 weeks, are recommended to use VIFERON 150,000 IU, 1 suppository 2 times a day every 12 hours daily for 5 days. According to clinical indications, therapy can be continued. The break between courses is 5 days.
Premature newborns with a gestational age of less than 34 weeks are recommended to use the drug VIFERON 150,000 IU, 1 suppository 3 times a day every 8 hours daily for 5 days. According to clinical indications, therapy can be continued. The break between courses is 5 days.
Infectious and inflammatory diseases of newborns, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy.
Read more…
The recommended dose for newborns, including premature babies with a gestational age of more than 34 weeks, is VIFERON 150,000 IU daily, 1 suppository 2 times a day after 12 hours. The course of treatment is 5 days.
Premature newborns with a gestational age of less than 34 weeks are recommended to use the drug VIFERON 150,000 IU daily, 1 suppository 3 times a day after 8 hours. The course of treatment is 5 days.
The recommended number of courses for various infectious and inflammatory diseases: sepsis - 2-3 courses, meningitis - 1-2 courses, herpes infection - 2 courses, enterovirus infection - 1-2 courses, cytomegalovirus infection - 2-3 courses, mycoplasmosis, candidiasis, including visceral, - 2-3 courses. The break between courses is 5 days. According to clinical indications, therapy can be continued.
Chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of severe activity, complicated by liver cirrhosis.
Read more…
The recommended dose for adults is VIFERON 3,000,000 IU, 1 suppository 2 times a day every 12 hours every day for 10 days, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.
The drug is used 2 times a day after 12 hours for the first 10 days daily, then three times a week every other day for 6–12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.
The calculation of the daily dose of the drug for each patient is made by multiplying the recommended dose for a given age by the body surface area calculated from the nomogram to calculate the body surface area by height and weight according to Harford, Terry and Rourke. The calculation of a single dose is carried out by dividing the calculated daily dose by 2 injections, the resulting value is rounded up to the suppository dosage up.
In chronic viral hepatitis of severe activity and liver cirrhosis, before plasmapheresis and / or hemosorption, it is recommended to use VIFERON 150,000 IU in children under 7 years of age, VIFERON 500,000 IU in children over 7 years of age, 1 suppository 2 times a day after 12 h daily for 14 days.
Infectious and inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults, including pregnant women, as part of complex therapy.
Pregnant women from the II trimester of pregnancy (starting from the 14th week of gestation) are recommended to use the drug VIFERON 500,000 IU, 1 suppository 2 times a day after 12 hours daily for 10 days, then for 9 days 3 times with an interval of 3 days ( on the fourth day) 1 suppository 2 times a day after 12 hours. Then every 4 weeks until delivery - VIFERON 150,000 IU, 1 suppository 2 times a day every 12 hours daily for 5 days.
If necessary, it is indicated before delivery (from the 38th week of gestation) the use of the drug VIFERON 500,000 IU, 1 suppository 2 times a day after 12 hours daily for 10 days.
Primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild and moderate course, including the urogenital form in adults, including pregnant women.
Read more…
The recommended dose for adults is VIFERON 1,000,000 IU, 1 suppository 2 times a day every 12 hours every day for 10 days or more in case of recurrent infection. According to clinical indications, therapy can be continued. It is recommended to start treatment immediately when the first signs of skin and mucous membrane lesions (itching, burning, redness) appear. In the treatment of recurrent herpes, it is desirable to start treatment in the prodromal period or at the very beginning of the manifestation of signs of relapse.
Pregnant women from the II trimester of pregnancy (starting from the 14th week of gestation) are recommended to use the drug VIFERON 500,000 IU, 1 suppository 2 times a day after 12 hours daily for 10 days, then for 9 days 3 times with an interval of 3 days ( on the fourth day) 1 suppository 2 times a day after 12 hours. Then every 4 weeks until delivery - VIFERON 150,000 IU, 1 suppository 2 times a day after 12 hours daily for 5 days. If necessary, it is indicated before delivery (from the 38th week of gestation) the use of the drug VIFERON 500,000 IU, 1 suppository 2 times a day after 12 hours daily for 10 days.
One suppository contains
active substance - interferon alpha-2b human recombinant 150,000 IU, 500,000 IU, 1,000,000 IU, 3,000,000 IU,
Excipients: ascorbic acid, sodium ascorbate, alpha-tocopherol acetate, disodium edetate dihydrate, polysorbate-80, cocoa butter, confectionery fat or cocoa butter substitute.
Description
Bullet-shaped suppository from white-yellow to yellow. Non-uniformity of coloring in the form of inclusions or marbling is allowed. On the longitudinal section there is a funnel-shaped depression. The diameter of the suppository is not more than 10 mm.
Pharmacotherapeutic group
Immunomodulators. Interferons. Interferon alfa-2b.
ATX code L03AB05
Pharmacological properties
Pharmacokinetics
Rectal application of the drug VIFERON® promotes a longer circulation of interferon in the blood than with intravenous or intramuscular injection interferon alpha-2b human recombinant.
A decrease in the level of serum interferon 12 hours after the administration of VIFERON® necessitates its repeated administration.
An analysis of the dynamics of the content of endogenous interferon in premature newborns with a gestational age of less than 34 weeks indicates the need to administer the drug VIFERON® 3 times a day after 8 hours.
Pharmacodynamics
Interferon alpha-2b human recombinant has pronounced antiviral, antiproliferative and immunomodulatory properties.
The complex composition of the drug causes a number of new effects:
in the presence of ascorbic acid and tocopherol acetate, the specific antiviral activity of interferon alpha-2b human recombinant increases, its immunomodulatory effect on T- and B-lymphocytes increases, the level
immunoglobulin E, the functioning of the endogenous interferon system is restored, there are no side effects that occur with parenteral administration of interferon preparations. It has been established that when using the drug VIFERON®
within 2 years, antibodies are not formed that neutralize the antiviral activity of interferon alpha-2b human recombinant, the functioning of the endogenous system of interferon is normalized.
Indications for use
- infectious and inflammatory diseases in newborns, including premature babies (as part of complex therapy)
acute respiratory viral infections (ARVI), pneumonia (bacterial, viral, chlamydial), meningitis, sepsis, specific intrauterine infection (chlamydia, herpes, cytomegaly, enterovirus infection, visceral candidiasis, mycoplasmosis)
- chronic viral hepatitis B, C, D in children and adults (as part of complex therapy), as well as in combination with viferon therapy
with the use of plasmapheresis and hemosorption of chronic viral hepatitis of a pronounced degree of activity and cirrhosis of the liver
- urogenital infection in pregnant women(chlamydia, genital herpes, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, human papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) as an interferon-correcting agent
- influenza and other acute respiratory viral diseases, including those complicated by bacterial infections in adults
(as part of complex therapy)
Dosage and administration
The drug is used rectally.
Children under 7 years old are prescribed VIFERON® 150,000 IU, children over 7 years old and adults - VIFERON® 500,000 IU.
VIFERON® 1000000 IU, VIFERON® 3000000 IU are prescribed primarily for the treatment of viral hepatitis in children and adults.
In the complex therapy of various infectious and inflammatory diseases in newborns, including premature babies
Newborn children VIFERON® 150000 IU are prescribed
1 suppository 2 times a day after 12 hours. The course of treatment is 5 days.
ARVI - 1 course, pneumonia (bacterial - 1-2 courses, viral - 1 course, chlamydial - 1 course), sepsis - 2-3 courses, meningitis - 1-2 courses, herpes infection - 2 courses, enterovirus infection - 1- 2 courses, cytomegalovirus infection - 2-3 courses, mycoplasmosis - 2-3 courses.
The break between courses is 5 days.
For premature newborns with a gestational age of less than 34 weeks, VIFERON® 150,000 IU is prescribed 1 suppository 3 times
per day after 8 hours. The course of treatment is 5 days.
In the complex therapy of chronic viral hepatitis B, C, D in children and adults, as well as in combination with viferon therapy using plasmapheresis and hemosorption of chronic viral hepatitis of a pronounced degree of activity and liver cirrhosis
For children with chronic viral hepatitis, the drug is prescribed
in the following age dosages:
up to 6 months daily dose 300000 IU,
from 6 to 12 months - 500,000 IU-1,000,000 IU (depending on height and weight),
from 1 year to 3 years - 1000000 IU-2000000 IU,
from 3 to 7 years - 2000000 IU-3000000 IU,
older than 7 years - 4000000 IU-5000000 IU.
In the morning and in the evening it is possible to use different dosages, for example: morning - 1 million IU, at night 500 thousand IU. The drug is used 2 times a day after 12 hours for the first 10 days daily, then three times a week every other day
within 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters. Children with chronic viral hepatitis of a pronounced degree of activity and cirrhosis of the liver before plasmapheresis and / or hemosorption are shown to use the drug for 14 days daily, 1 suppository 2 times a day after 12 hours (children under 7 years old VIFERON® 150,000 IU, children over 7 years old - VIFERON® 500000 IU).
Adults with chronic viral hepatitis are prescribed
VIFERON® 3000000 IU 1 suppository 2 times a day through
12 hours for 10 days daily, then three times a week every other day
within 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.
As an interferon-correcting agent in pregnant women
with urogenital infection (chlamydia, genital herpes, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis)
In the complex therapy of pregnant women with urogenital infection
from 28 to 34 weeks of gestation, VIFERON® 150,000 IU is used
1 suppository 2 times a day after 12 hours every other day
(per course - 10 suppositories). From 35 weeks before delivery, VIFERON® 500,000 IU is used daily, 1 suppository 2 times a day after 12 hours for 5 days.
A total of 7 courses for 12 weeks, starting from the 28th week of gestation, a break between courses is 7 days. The duration of treatment is determined by clinical efficacy and laboratory parameters.
In the complex therapy of influenza and other acute respiratory viral diseases, including those complicated by bacterial infection
in adults
Apply VIFERON® 500000 IU 1 suppository 2 times a day every 12 hours every day. The course of treatment is 5 days.
Side effects"type="checkbox">
Side effects
Rarely - allergic reactions (skin rashes and itching). These phenomena are reversible and disappear 72 hours after discontinuation of the drug.
Contraindications
Hypersensitivity to active ingredient or excipients
Pregnancy period up to 28 weeks
Drug Interactions"type="checkbox">
Drug Interactions
VIFERON® is compatible and goes well with all medicines used in the treatment of these diseases (antibiotics, chemotherapy, glucocorticosteroids, immunosuppressants).
Viferon is an antimicrobial and antiviral drug. Instructions for use recommend taking candles 150,000 IU, 500,000 IU, 1,000,000 IU, gel, ointment for the complex therapy of various inflammatory and infectious diseases in adults and children. Reviews of patients and doctors confirm that this drug helps in the treatment of hepatitis, herpes, influenza and other infectious diseases.
Release form and composition
Viferon is produced in the form of:
- suppositories for rectal use (suppositories) - bullet-shaped, homogeneous consistency, white with a yellowish tint, with a diameter of up to 10. 1 suppository contains: human recombinant interferon alfa-2b - 150,000, 500,000, 1,000,000 or 3,000,000 IU.
- ointment for local and external use - homogeneous, viscous, yellowish-white or yellow in color, with a specific smell of lanolin. The composition of 1 g of the ointment includes: human recombinant interferon alfa-2b - 40,000 International units (IU).
- gel for local and external use - gel-like, opaque, homogeneous white mass with a grayish tint. The composition of 1 g of the gel includes: human recombinant interferon alpha-2b - 36,000 IU.
As excipients, the composition of the drug includes tocopherol acetate and ascorbic acid.
pharmachologic effect
Due to the presence of tocopherol acetate and ascorbic acid, the antiviral activity of interferon increases significantly, its effect on B- and T-lymphocytes increases, the functions of the endogenous system are restored, and the parameters of immunoglobulin E are normalized.
Long-term use of the drug does not lead to the formation of specific antibodies that neutralize the antiviral activity of interferon.
The use of Viferon ointment and suppositories helps to significantly reduce the dosage and duration of the course of treatment. hormonal means, antibiotics and cytostatics.
With rectal use, a decrease in the concentration of interferon in the blood occurs after twelve hours, which is much longer than with the introduction of interferon intravenously. The drug for children at a gestational age of less than 34 weeks is excreted faster, so re-administration of the drug in this case is required after eight hours.
What helps Viferon?
Indications for the use of an ointment or gel include:
- treatment of viral (including those caused by the herpes virus) infections of the skin and mucous membranes.
- treatment of chronic recurrent herpetic infection of various localization in women;
- prevention and treatment of recurrent stenosing laryngotracheobronchitis in children;
- prevention and treatment of children with frequent acute respiratory infections.
Why are Viferon candles prescribed? Suppositories are indicated if the patient has:
- influenza and other acute respiratory viral infections and acute respiratory infections, incl. complicated by a bacterial infection, in adults;
- various infectious and inflammatory diseases in children, incl. newborns and premature babies: SARS, influenza, incl. complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial), meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, CMV infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis);
- chronic viral hepatitis B, C, D in children and adults, incl. in combination with the use of plasmapheresis and hemosorption, chronic viral hepatitis of a pronounced degree of activity and complicated by cirrhosis of the liver;
- adults, incl. pregnant women with urogenital infections (chlamydia, CMV infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis), primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild and moderate course, incl. h. urogenital localization.
Instructions for use
Candles Viferon
Acute respiratory viral infections, including influenza, incl. complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy.
The recommended dose for adults, including pregnant women and children over 7 years old, is Viferon 500,000 IU, 1 suppository 2 times a day. every 12 hours daily for 5 days. According to clinical indications, therapy can be continued.
Children under 7 years old, incl. newborns and premature babies with a gestational age of more than 34 weeks are prescribed Viferon 150,000 IU, 1 suppository 2 times / day. every 12 hours daily for 5 days. According to clinical indications, therapy can be continued. The break between courses is 5 days.
Premature newborns with a gestational age of less than 34 weeks are prescribed Viferon 150,000 IU, 1 suppository 3 times / day. every 8 hours daily for 5 days. According to clinical indications, therapy can be continued. The break between courses is 5 days.
Treatment of infectious pathologies
Infectious and inflammatory diseases of newborns, incl. premature, such as meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy. 
- The recommended dose for newborns, incl. premature babies with a gestational age of more than 34 weeks - Viferon 150,000 IU daily, 1 suppository 2 times / day. after 12 hours. The course of treatment is 5 days.
- Premature newborns with a gestational age of less than 34 weeks are prescribed Viferon 150,000 IU daily, 1 suppository 3 times / day. after 8 hours. The course of treatment is 5 days.
The recommended number of courses for various infectious and inflammatory diseases: sepsis - 2-3 courses, meningitis - 1-2 courses, herpes infection - 2 courses, enterovirus infection - 1-2 courses, cytomegalovirus infection - 2-3 courses, mycoplasmosis, candidiasis, including visceral - 2-3 courses. The break between courses is 5 days. According to clinical indications, therapy can be continued.
Chronic viral hepatitis B, C, D in children and adults as part of complex therapy, incl. in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of severe activity, complicated by cirrhosis of the liver:
- The recommended dose for adults is Viferon 3,000,000 IU, 1 suppository 2 times a day. after 12 hours daily for 10 days, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.
- Children under 6 months of age are recommended 300,000-500,000 IU/day; at the age of 6 to 12 months - 500,000 ME / day.
- Children aged 1 to 7 years are recommended 3,000,000 ME per 1 sq.m. body surface area/day
- Children over 7 years old are recommended 5,000,000 ME per 1 sq.m. body surface area/day
The drug is used 2 times / day. after 12 hours the first 10 days daily, then - three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.
Instructions for use of the gel and ointment
Gel and ointment Viferon is applied externally topically.
As part of the complex therapy of acute respiratory viral infections, including influenza, long-term and frequent acute respiratory viral infections, incl. complicated by a bacterial infection: a strip of gel no longer than 0.5 cm is applied to the previously dried surface of the nasal mucosa and / or to the surface of the palatine tonsils 3-5 times / day. using a spatula or cotton swab / cotton swab. The course of treatment is 5 days, if necessary, the course can be extended.
Prevention of acute respiratory viral infections, including influenza: during the period of rising incidence, a strip of gel no longer than 0.5 cm is applied to the previously dried surface of the nasal mucosa and / or to the surface of the palatine tonsils 2 times / day. within 2-4 weeks.
As part of the complex therapy of recurrent stenosing laryngotracheobronchitis: a strip of gel no longer than 0.5 cm is applied to the surface of the palatine tonsils with a spatula or cotton swab / cotton swab in the acute period of the disease 5 times / day. within 5-7 days, then 3 times / day. over the next 3 weeks.
Prevention of recurrent stenosing laryngotracheobronchitis: a strip of gel no longer than 0.5 cm is applied to the surface of the palatine tonsils with a spatula or cotton swab / cotton swab 2 times / day. within 3-4 weeks, the courses are repeated 2 times a year.
Treatment of herpetic infections
As part of the complex therapy of herpetic cervicitis: 1 ml of the gel is applied with a cotton swab to the surface of the cervix previously cleared of mucus 2 times / day. within 7 days, if necessary, the duration of the course can be increased up to 14 days.
As part of the complex therapy of acute and chronic recurrent herpetic infection (when the first signs of the disease appear or during the period of precursors): a strip of gel no longer than 0.5 cm is applied with a spatula or a cotton swab / cotton swab to a previously dried affected surface 3-5 times / day . within 5-6 days. If necessary, the duration of the course is increased until the disappearance of clinical manifestations.
Contraindications
- hypersensitivity to the components of the drug Viferon, from which the ointment and suppositories can cause side effects;
- first trimester of pregnancy (for suppositories);
- children's age up to 1 year (for ointment).
Side effects
The medicine is well tolerated. In rare cases, allergic reactions are observed.
Children, during pregnancy and lactation
Ointment is contraindicated in children under 1 year. Cream and suppositories are used in childhood according to the recommended dosing regimen.
special instructions
Possible allergic reactions are reversible and disappear 72 hours after the end of the drug.
drug interaction
Viferon goes well with everyone medicines used in the treatment of viral and other diseases (chemotherapeutic agents, antibiotics, glucocorticosteroids).
Viferon's analogs
The analogue in structure is the drug Interal-P.
Holiday conditions and price
The average price of the drug Viferon (suppositories 150 thousand IU No. 10) in Moscow is 230 rubles. In Kyiv, you can buy medicine for 278 hryvnia, in Kazakhstan - for 1855 tenge. In Minsk, pharmacies offer candles for 14 bel. rubles. It is dispensed from pharmacies without a medical prescription.
Post Views: 1 281
.
If you have questions about the use of Viferon suppositories during pregnancy, see the article.
If you are not sure how to enter rectal suppositories Viferon, see the article.
Viferon price: in Moscow, Ukraine, Belarus.
About the correct selection of the dosage of Viferon suppositories in questions and answers, read the article
Information on how to properly store Viferon candles in the form of questions and answers can be found in the article
Trade name of the medicinal product
Viferon (VIFERON)®Manufacturer
Feron LLC, RussiaInternational non-proprietary name
Interferon human recombinant alpha-2Dosage form
Suppositories rectalRelease form
Suppositories (150,000 IU, 500,000 IU, 1,000,000 IU, 3,000,000 IU) weighing from 0.95 g to 1.05 g, 10 pieces each in a PVC/paper blister pack or weighing from 1.00 g to 1.10 g, 10 pieces in blisters PVC/PVC. 1 or 2 blister packs with instructions for use in a cardboard packDescription
The suppository has a bullet shape, yellowish-white color, uniform consistency. Color heterogeneity in the form of marbling and the presence of a funnel-shaped depression on the cut is allowed. The diameter of the suppository is not more than 10 mm.Pharmacotherapeutic group
Immunomodulatory and antiviral agent.Active substance
1 suppository VIFERON 150,000 IU contains the active substance - interferon human recombinant alpha-2 150,000 IU;1 suppository VIFERON 500000 IU contains the active substance - interferon human recombinant alpha-2 500000 IU
1 suppository VIFERON 1000000 IU contains the active substance - interferon human recombinant alpha-2 1000000 IU
1 suppository VIFERON 3000000 IU contains the active substance - interferon human recombinant alpha-2 3000000 IU
Excipients
Ascorbic acid 0.015 g, alpha-tocopherol acetate 0.055 g, base cocoa butter or solid fatpharmachologic effect
Interferon human recombinant alpha-2 has pronounced antiviral, immunomodulatory and antiproliferative properties. The complex composition of the drug causes a number of additional effects: in the presence of ascorbic acid and alpha-tocopherol acetate, the antiviral activity of human recombinant interferon alpha-2 increases, its immunomodulatory effect on T- and B-lymphocytes increases, the level of immunoglobulin E normalizes, and the functioning of the endogenous system is restored interferon. In addition, ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and regenerating properties. It has been established that when using VIFERON, there are no side effects that occur with parenteral administration of interferon preparations, and antibodies are not formed that neutralize the antiviral activity of interferon.Pharmacokinetics
After rectal administration, after 12 hours, a decrease in serum concentration is observed, which necessitates its repeated administration.Indications for use
In the complex therapy of various infectious and inflammatory diseases in children, including newborns and premature babies:- acute respiratory viral infections (influenza, SARS, including those complicated by a bacterial infection),
- pneumonia (bacterial, viral, chlamydial),
- meningitis (bacterial, viral),
- sepsis,
- intrauterine infection (chlamydia, herpes, cytomegaly, enterovirus infection, candidiasis, including visceral, mycoplasmosis);
with chronic viral hepatitis of a pronounced degree of activity and complicated by cirrhosis of the liver;
in complex therapy in adults, including pregnant women, with urogenital infection(chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis),
primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild and moderate course, including urogenital form;
in complex therapy, including those complicated by a bacterial infection in adults.
Dosing regimen
Suppositories containing human recombinant alpha-2 interferon as an active substance in the indicated dosages (150,000 IU, 500,000 IU, 1,000,000 IU, 3,000,000 IU) are used rectally.In the complex therapy of various infectious and inflammatory diseases in newborns, including premature: newborns, including premature babies with gestational age over 34 weeks appoint VIFERON 150,000 IU * daily, 1 suppository 2 times a day after 12 hours. The course of treatment is 5 days.
Preterm infants with gestational age less than 34 weeks appoint VIFERON 150,000 IU daily, 1 suppository 3 times a day after 8 hours. The course of treatment is 5 days.
The recommended number of courses for various infectious and inflammatory diseases in children, including newborns and premature:
- influenza, SARS, including those complicated by a bacterial infection - 1-2 courses;
- pneumonia(bacterial, viral, chlamydial) - 1-2 courses,
- sepsis- 2-3 courses,
- meningitis- 1-2 courses,
- herpetic infection– 2 courses,
- enterovirus infection- 1-2 courses,
- cytomegalovirus infection - 2-3 courses,
- mycoplasmosis, candidiasis, including visceral, - 2-3 courses.
In complex therapy chronic viral hepatitis B, C, D in children and adults: for children with chronic viral hepatitis, the drug is prescribed in the following age dosages: up to 6 months 300,000-500,000 IU per day; 6 to 12 months- 500,000 IU per day. Aged from 1 year to 7 years- 3,000,000 IU per 1 m2 of body surface area per day. Aged over 7 years old- 5,000,000 IU per 1 m2 of body surface area per day. for each individual patient is produced by multiplying the recommended dosage for a given age by the body surface area, calculated according to nomogram to calculate the body surface area in height and weight according to Harford, Terry and Rourke, divided into 2 injections, rounded up to the dosage of the appropriate suppository. The drug is used 2 times a day after 12 hours for the first 10 days daily, more three times a week every other day for 6-12 months.
The duration of treatment is determined by clinical efficacy and laboratory parameters. Children with chronic viral hepatitis with a pronounced degree of activity and liver cirrhosis before the plasmapheresis and/or hemosorption indicated the use of the drug for 14 days daily, 1 suppository 2 times a day after 12 hours(for children under 7 years old VIFERON 150,000 IU, for children over 7 years old - VIFERON 500,000 IU).
Adults with chronic viral hepatitis appoint VIFERON 3000000 IU 1 suppository 2 times a day after 12 hours for 10 days daily, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.
In complex therapy, adults, including pregnant women, with urogenital infection(chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis), with primary or recurrent herpetic infection skin and mucous membranes (localized form, mild and moderate course, including urogenital form).
Adults, with the above infections, except for herpes, are prescribed Viferon 500000 IU on 1 suppository 2 times a day after 12 hours. The course is 5-10 days. According to clinical indications, therapy can be continued with intervals between courses of 5 days.
At herpetic infection appoint VIFERON 1000000 IU 1 suppository 2 times a day after 12 hours. The course of treatment is 10 days or more with recurrent infection. It is recommended to start treatment immediately when the first signs of skin and mucous membrane lesions (itching, burning, redness) appear. In the treatment of recurrent herpes, it is desirable to start treatment in the prodromal period or at the very beginning of the manifestation of signs of relapse.
At pregnant women with urogenital infection, including herpetic, in the II trimester of pregnancy (starting from the 14th week) - Viferon 500,000 IU 1 suppository every 12 hours (2 times a day) for 10 days, then 1 suppository every 12 hours (2 times a day) twice a week - 10 days. Then, after 4 weeks, preventive courses of the drug Viferon are carried out. 150,000 IU 1 suppository every 12 hours - for 5 days, the prophylactic course is repeated every 4 weeks. If necessary, it is possible to conduct a treatment course before childbirth.
Separate article. In complex therapy influenza and other acute respiratory viral diseases, including those complicated by bacterial infection in adults. Apply VIFERON 500000 IU 1 suppository 2 times a day every 12 hours daily. The course of treatment is 5-10 days.
Contraindications
Hypersensitivity to any of the components of the drugPregnancy and lactation
The drug is approved for use from the 14th week of pregnancy. It has no restrictions for use during lactation.Side effect
In rare cases, the development of allergic reactions (skin rashes, itching) is possible. These phenomena are reversible and disappear 72 hours after discontinuation of the drug.special instructions
It is possible to use as part of combination therapy with antibacterial drugs, corticosteroids, immunosuppressive drugs, interferon inducers.Overdose
Data not provideddrug interaction
VIFERON, rectal suppositories, compatible and well combined with all drugs used in the treatment of the above diseases (antibiotics, chemotherapy drugs, glucocorticosteroids)Shelf life
2 years. Do not use the drug after the expiration dateStorage conditions
In a place protected from light, at a temperature of 2 to 8 ° C. Transportation and storage in accordance with SP 3.3.2.1248-03 at a temperature of 2 to 8 ° C. Store out of the reach of childrenTerms of dispensing from pharmacies
Without a doctor's prescriptionapproximate price
Russia: 150,000 IU $5.3-7, 500,000 IU $7.9-9.5, 1,000,000 IU $10.9-13.8, 3,000,000 IU $18.7-21.1Belarus: 150,000 IU $10-14.3, 500,000 IU $13.9-19.4